Status:
COMPLETED
A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborating Sponsors:
Ariad Pharmaceuticals
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is being done to find the best tolerated dose of ridaforolimus and dalotuzumab in patients who have advanced cancer and to observe any anti-tumor activity in these patients.
Detailed Description
Ridaforolimus (MK8669/AP23573) was also known as deforolimus until May 2009
Eligibility Criteria
Inclusion
- You must have confirmed metastatic or advanced cancer that has not responded to standard therapy or where standard therapy does not exist
- In Part C, patients must have a diagnosis of advanced or metastatic colorectal adenocarcinoma or non-small cell lung cancer, and must have received at least 1 but no more than three prior systemic therapy treatment regimens
- You must be over the age of 18 years old
- You must have a ECOG status performance of 0 or 1
- You must have good organ function
- You must be willing to have skin and/or tumor biopsies
Exclusion
- You have had cancer treatment within 4 weeks prior to entering the study or you still have bad side effects from previous therapies
- You have an active infection that requires treatment
- You are HIV positive or have a history of Hepatitis B or C
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT00730379
Start Date
July 1 2008
End Date
November 1 2010
Last Update
February 10 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.